RxDoctor Payments Data

Todd Hagle, MD

Pain Medicine · Saint Charles, ILNPI 1609929462

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,674 of the $7,485 with a category attached, or 62.4%. It is spread thinly across 26 manufacturers, the largest accounting for just 21.1%. Reporting peaked in 2023 at $3,296 and has fallen 67.5% since, to $1,073 in 2025.

$7,485in general payments, 2019–2025

Across 149 payments — averaging $50.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Genesys Orthopedics Systems, L.L.C.$2K
  • Relievant Medsystems, Inc.$942
  • Boston Scientific$857
  • Nevro Corp.$797
  • Collegium Pharmaceutical, Inc.$535
  • plus $1K from 20 others

What the payments were for

  • Travel & lodging$2,76137%
  • Food & beverage$4,67462%
  • Education$350%
  • Gifts$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,485 in reported general payments places this provider in the 75th percentile of 233 pain medicine providers in Illinois.

See all pain medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$277,818
Medicare patients
266
Services billed
4,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen513$14,560
OxycontinOxycodone Hcl15$5,702
Xtampza ErOxycodone Myristate15$5,700
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen152$4,263
Celecoxib67$3,165
Gabapentin220$2,890
Baclofen191$2,846
Duloxetine Hcl139$2,492
Pregabalin153$2,308
Oxycodone Hcl112$1,893
Morphine Sulfate ErMorphine Sulfate84$1,547
Cyclobenzaprine Hcl66$1,490
Tramadol Hcl ErTramadol Hcl18$1,025
Acetaminophen-CodeineAcetaminophen With Codeine43$744
Morphine Sulfate25$728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$535$5,70015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 233 pain medicine providers in Illinois.

Other pain medicine in Saint Charles

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →